Zydus Lifesciences on 21 September announced that it had received final approval from the USFDA (United States Food and Drug Administration) for a skin-care gel used to treat acne.

The company said in its regulatory filing, “We have received final approval from the USFDA for Clindamycin Phosphate Gel USP. Clindamycin is an antibiotic which works by stopping the growth of bacteria and helps to decrease the number of acne lesions. It had annual sales of USD 37 mn in the United States as per July 2023 figures of IQVIA MAT.”

The said drug will be manufactured at the company’s tropical manufacturing facility at Changodar, Ahmedabad.

The company is in the business of manufacturing, developing, and marketing a wide range of pharmaceutical products that include API (active pharmaceutical ingredients) and generic drugs.

In its quarterly report for the April-June quarter, the company reported a 96.87% YoY increase in its net profit to Rs 1,134 crore and a 26.19% YoY increase in its revenue from operations to Rs 5,140 crore.